Advancements in the treatment of metastatic breast cancer (MBC): The role of ixabepilone

Journal of Oncology

Volumn , Issue , 2012, Pages

  Cristofanilli, Massimo ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; GEMCITABINE; INIPARIB; IXABEPILONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; SURVIVAL TIME;

EID: 84862301244     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/703858     Document Type: Review

References (60)

1. Desantis C., Siegel R., Bandi P., Jamal A., Breast cancer statistics, 2011 CA: A Cancer Journal for Clinicians 2011 61 6 408 418
2. ACS. Cancer Facts Figures, 2011, http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
3. Guarneri V., Conte P., Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy Oncologist 2009 14 7 645 656
4. Perou C. M., Srile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge., Pergammenschlkov A., Williams C., Zhu S. X., Lnning P. E., Brresen-Dale A. L., Brown P. O., Botstein D., Molecular portraits of human breast tumours Nature 2000 406 6797 747 752
5. Srlie T., Tibshirani R., Parker J., Hastie T., Marron J. S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C. M., Lnning P. E., Brown P. O., Brresen-Dale A. L., Botstein D., Repeated observation of breast tumor subtypes in independent gene expression data sets Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8418 8423 (Pubitemid 36842560)
6. Sotiriou C., Neo S. Y., McShane L. M., Korn E. L., Long P. M., Jazaeri A., Martiat P., Fox S. B., Harris A. L., Liu E. T., Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10393 10398 (Pubitemid 37071889)
7. Perreard L., Fan C., Quackenbush J. F., Mullins M., Gauthier N. P., Nelson E., Mone M., Hansen H., Buys S. S., Rasmussen K., Orrico A. R., Dreher D., Walters R., Parker J., Hu Z., He X., Palazzo J. P., Olopade O. I., Szabo A., Perou C. M., Bernard P. S., Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay Breast Cancer Research 2006 8 2, article no. R23
8. Fojo A. T., Menefee M., Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR) Seminars in Oncology 2005 32 7 S3 S8
9. Geney R., Ungureanu I. M., Li D., Ojima I., Overcoming multidrug resistance in taxane chemotherapy Clinical Chemistry and Laboratory Medicine 2002 40 9 918 925 (Pubitemid 35277418)
10. Rowinsky E. K., The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents Annual Review of Medicine 1997 48 353 374 (Pubitemid 27101837)
11. Hudis C. A., Gianni L., Triple-negative breast cancer: an unmet medical need The oncologist 2011 16, supplement 1 1 11
12. Orr G. A., Verdier-Pinard P., McDaid H., Horwitz S. B., Mechanisms of Taxol resistance related to microtubules Oncogene 2003 22 47 7280 7295 (Pubitemid 37487160)
13. Hari M., Yang H., Zeng C., Canizales M., Cabral F., Expression of class III -tubulin reduces microtubule assembly and confers resistance to paclitaxel Cell Motility and the Cytoskeleton 2003 56 1 45 56 (Pubitemid 37059485)
14. Shalli K., Brown I., Heys S. D., Schofield A. C., Alterations of -tubulin isotypes in breast cancer cells resistant to docetaxel FASEB Journal 2005 19 10 1299 1301 (Pubitemid 41113729)
15. Tommasi S., Mangia A., Lacalamita R., Bellizzi A., Fedele V., Chiriatti A., Thomssen C., Kendzierski N., Latorre A., Lorusso V., Schittulli F., Zito F., Kavallaris M., Paradiso A., Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of -tubulins International Journal of Cancer 2007 120 10 2078 2085 (Pubitemid 46555844)
16. Alli E., Sharma V. B., Sunderesakumar P., Ford J. M., Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase Cancer Research 2009 69 8 3589 3596
17. Rottenberg S., Jaspers J. E., Kersbergen A., Van Der Burg E., Nygren A. O. H., Zander S. A. L., Derksen P. W. B., De Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M. J., Martin N. M. B., Borst P., Jonkers J., High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proceedings of the National Academy of Sciences of the United States of America 2008 105 44 17079 17084
18. Bryant H. E., Schultz N., Thomas H. D., Parker K. M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N. J., Helleday T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005 434 7035 913 917 (Pubitemid 40559005)
19. Farmer H., McCabe H., Lord C. J., Tutt A. H. J., Johnson D. A., Richardson T. B., Santarosa M., Dillon K. J., Hickson I., Knights C., Martin N. M. B., Jackson S. P., Smith G. C. M., Ashworth A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 7035 917 921 (Pubitemid 40559006)
20. O'Shaughnessy J., Osborne C., Pippen J. E., Yoffe M., Patt D., Rocha C., Koo I. C., Sherman B. M., Bradley C., Iniparib plus chemotherapy in metastatic triple-negative breast cancer New England Journal of Medicine 2011 364 3 205 214
21. OShaughnessy J., Schwartzberg L. S., Danso M. A., A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) Journal of Clinical Oncology 2011 29 supplement 15s, abstract 1007
22. Cortes J., O'Shaughnessy J., Loesch D., Blum J. L., Vahdat L. T., Petrakova K., Chollet P., Manikas A., Diéras V., Delozier T., Vladimirov V., Cardoso F., Koh H., Bougnoux P., Dutcus C. E., Seegobin S., Mir D., Meneses N., Wanders J., Twelves C., Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study The Lancet 2011 377 9769 914 923
23. Bode C. J., Gupta M. L., Reiff E. A., Suprenant K. A., Georg G. I., Himes R. H., Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules Biochemistry 2002 41 12 3870 3874 (Pubitemid 34251025)
24. Bollag D. M., McQueney P. A., Zhu J., Hensens O., Koupal L., Liesch J., Goetz M., Lazarides E., Woods C. M., Epothilones, a new class of microtubule-stabilizing agents with a taxol- like mechanism of action Cancer Research 1995 55 11 2325 2333
25. Giannakakou P., Gussio R., Nogales E., Downing K. H., Zaharevitz D., Bollbuck B., Poy G., Sackett D., Nicolaou K. C., Fojo T., A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proceedings of the National Academy of Sciences of the United States of America 2000 97 6 2904 2909 (Pubitemid 30159270)
26. Chuang E., Wiener N., Christos P., Kessler R., Cobham M., Donovan D., Goldberg G. L., Caputo T., Doyle A., Vahdat L., Sparano J. A., Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary Annals of Oncology 2010 21 10 2075 2080
27. Hunt J. T., Discovery of Ixabepilone Molecular Cancer Therapeutics 2009 8 2 275 281
28. Lee F. Y., Borzilleri R., Fairchild C. R., Kim S. H., Long B. H., Reventos-Suarez C., Vite G. D., Rose W. C., Kramer R. A., BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clinical Cancer Research 2001 7 5 1429 1437 (Pubitemid 32708699)
29. Lee F. Y., Camuso A., Castenada S., Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types Proceedings of the American Association of Cancer Research Annual Meeting April 2006 Washington, DC, USA abstract 503
30. Jordan M., Miller H., Ni L., The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone Proceedings of the American Association for Cancer Research Annual Meeting April 2006 Washington, DC, USA abstract LB-280
31. Perez E. A., Patel T., Moreno-Aspitia A., Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer Breast Cancer Research and Treatment 2010 121 2 261 271
32. Lee F. Y., Smykla R., Johnston K., Menard K., McGlinchey K., Peterson R. W., Wiebesiek A., Vite G., Fairchild C. R., Kramer R., Preclinical efficacy spectrum and pharmacokinetics of ixabepilone Cancer Chemotherapy and Pharmacology 2009 63 2 201 212
33. Rivera E., Lee J., Davies A., Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors Oncologist 2008 13 12 1207 1223
34. Goodin S., Kane M. P., Rubin E. H., Epothilones: mechanism of action and biologic activity Journal of Clinical Oncology 2004 22 10 2015 2025 (Pubitemid 41095195)
35. Ixempra PI, IXEMPRA Kit (ixabepilone) for Injection, Full Prescribing Information, Bristol-Myers Squibb, 2010
36. Perez E. A., Lerzo G., Pivot X., Thomas E., Vahdat L., Bosserman L., Viens P., Cai C., Mullaney B., Peck R., Hortobagyi G. N., Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine Journal of Clinical Oncology 2007 25 23 3407 3414 (Pubitemid 47310876)
37. Sparano J. A., Vrdoljak E., Rixe O., Xu B., Manikhas A., Medina C., Da Costa S. C., Ro J., Rubio G., Rondinon M., Perez Manga G., Peck R., Poulart V., Conte P., Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane Journal of Clinical Oncology 2010 28 20 3256 3263
38. Thomas E. S., Gomez H. L., Li R. K., Chung H. C., Fein L. E., Chan V. F., Jassem J., Pivot X. B., Klimovsky J. V., De Mendoza F. H., Xu B., Campone M., Lerzo G. L., Peck R. A., Mukhopadhyay P., Vahdat L. T., Roché H. H., Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment Journal of Clinical Oncology 2007 25 33 5210 5217 (Pubitemid 350232252)
39. Jassem J., Fein L., Karwal M., Campone M., Peck R., Poulart V., Vahdat L., Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies Breast 2012 21 1 89 94
40. Lee F. Y., Covello K. L., Castaneda S., Hawken D. R., Kan D., Lewin A., Wen M. L., Ryseck R. P., Fairchild C. R., Fargnoli J., Kramer R., Synergistic antitumor activity of ixabepilone (BMS-247550)plus bevacizumab in multiple in vivo tumor models Clinical Cancer Research 2008 14 24 8123 8131
41. Rugo H. S., Campone M., Amadori D., Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results Journal of Clinical Oncology 2010 28 15s 1040
42. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E. A., Shenkier T., Cella D., Davidson N. E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New England Journal of Medicine 2007 357 26 2666 2676
43. Smith J. W., Vukelja S. J., Rabe A. C., Final results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC) Proceedings of the Breast Cancer Symposium 2010 Abstract 268
44. Moulder S., Li H., Wang M., Gradishar W. J., Perez E. A., Sparano J. A., Pins M., Yang X., Sledge G. W., A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial Breast Cancer Research and Treatment 2010 119 3 663 671
45. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
46. Robert N., Leyland-Jones B., Asmar L., Belt R., Llegbodu D., Loesch D., Raju R., Valentine E., Sayre R., Cobleigh M., Albain K., McCullough C., Fuchs L., Slamon D., Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2overexpressing metastatic breast cancer Journal of Clinical Oncology 2006 24 18 2786 2792 (Pubitemid 46630577)
47. Awada A., Piccart M. J., Jones S. F., Peck R. A., Gil T., Lebwohl D., Wu C. Y., Burris H. A., Phase i dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy Cancer Chemotherapy and Pharmacology 2009 63 3 417 425
48. Denduluri N., Low J. A., Lee J. J., Berman A. W., Walshe J. M., Vatas U., Chow C. K., Steinberg S. M., Yang S. X., Swain S. M., Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes Journal of Clinical Oncology 2007 25 23 3421 3427 (Pubitemid 47310878)
49. Low J. A., Wedam S. B., Lee J. J., Berman A. W., Brufsky A., Yang S. X., Poruchynsky M. S., Steinberg S. M., Mannan N., Fojo T., Swain S. M., Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer Journal of Clinical Oncology 2005 23 12 2726 2734 (Pubitemid 46179462)
50. Roché H., Yelle L., Cognetti F., Mauriac L., Bunnell C., Sparano J., Kerbrat P., Delord J. P., Vahdat L., Peck R., Lebwohl D., Ezzeddine R., Curé H., Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy Journal of Clinical Oncology 2007 25 23 3415 3420 (Pubitemid 47310877)
51. Thomas E., Tabernero J., Fornier M., Conté P., Fumoleau P., Lluch A., Vahdat L. T., Bunnell C. A., Burris H. A., Viens P., Baselga J., Rivera E., Guarneri V., Poulart V., Klimovsky J., Lebwohl D., Martin M., Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer Journal of Clinical Oncology 2007 25 23 3399 3406 (Pubitemid 47310875)
52. Plummer R., Woll P., Fyfe D., Boddy A. V., Griffin M., Hewitt P., Carmichael J., Namouni F., Cohen M., Verrill M., A phase i and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies Clinical Cancer Research 2008 14 24 8288 8294
53. Tolaney S. M., Najita J., Chen W., A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer Cancer Research 2009 69, abstract 3137
54. Baselga J., Zambetti M., Llombart-Cussac A., Manikhas G., Kubista E., Steger G. G., Makhson A., Tjulandin S., Ludwig H., Verrill M., Ciruelos E., Egyhazi S., Xu L. A., Zerba K. E., Lee H., Clark E., Galbraith S., Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer Journal of Clinical Oncology 2009 27 4 526 534
55. Bear H. D., Anderson S., Smith R. E., Geyer C. E., Mamounas E. P., Fisher B., Brown A. M., Robidoux A., Margolese R., Kahlenberg M. S., Paik S., Soran A., Wickerham D. L., Wolmark N., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 Journal of Clinical Oncology 2006 24 13 2019 2027 (Pubitemid 46622110)
56. Wardley A., Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer Oncologist 2006 11 1 20 26
57. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B., Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 Journal of the National Cancer Institute Monographs 2001 30 96 102
58. Rosenberg K. J., Ross J. L., Feinstein H. E., Feinstein S. C., Israelachvili J., Complementary dimerization of microtubule-associated tau protein: implications for microtubule bundling and tau-mediated pathogenesis Proceedings of the National Academy of Sciences of the United States of America 2008 105 21 7445 7450 (Pubitemid 351830037)
59. Felgner H., Frank R., Biernat J., Mandelkow E. M., Mandelkow E., Ludin B., Matus A., Schliwa M., Domains of neuronal microtubule-associated proteins and flexural rigidity of microtubules Journal of Cell Biology 1997 138 5 1067 1075 (Pubitemid 27386456)
60. Choi M. C., Raviv U., Miller H. P., Gaylord M. R., Kiris E., Ventimiglia D., Needleman D. J., Kim M. W., Wilson L., Feinstein S. C., Safinya C. R., Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron X-ray scattering study Biophysical Journal 2009 97 2 519 527